Even more, CCL17/TARC and CCL22/MDC produced by both tumor and infiltrating cells in different types of cancer are able to recruit CCR4+ regulatory T and polarized Th2 cells that inhibit anti-tumor responses contributing to tumor survival [81,82]. Here, CCL22 is linked to neoplasm.